SeraCare Life Sciences Announces Strategic Partnership with ViveBio to EnableNext Generation Preanalytic Products for the IVD Industry
July 27, 2015
Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC Atlanta, Georgia, July 27, 2015 – SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced at the 2015 AACC Annual Meeting today that it has signed a strategic partnership agreement with ViveBio, LLC, a biotechnology company that develops, markets and sells preanalytic products based upon ViveST™ technology. Products enabled with ViveST™ allow sample collection, transport and storage in a dried, shelf stable format. Under the terms of the agreement, the two firms will jointly market and sell their combined technologies into the in vitro
diagnostic development market.
SeraCare develops, markets and sells a wide range of products, technologies and services that accelerate the development and commercial adoption of diagnostic assay development programs, including a wide range of natural and engineered infectious disease materials, in-kit controls and 3rd party reference materials. ViveBio has developed an innovative sample collection, storage and transport technology that has the potential to disrupt the traditional limitations on specimen collection in both resource poor regions and alternate site collections with its stabilizing matrix and room temperature storage.
“With the recent advances in breakthrough drug therapies for HIV, HCV and other virologic diseases, more of our key IVD customers are developing assays for the major global initiatives seeking to identify and subsequently treat those infected with the proper therapies.”, said Trevor W. Brown, Vice President of the SeraCare’s Precision Medicine Business Unit. “Combining SeraCare’s deep expertise in supporting advanced diagnostics development with ViveBio’s groundbreaking ViveST™ technology will give diagnostics developers economical solutions to specimen collection and stabilization, coupled with QC tools that will help improve the diagnostic reach and performance of these tests.”
“ViveBio is pleased to partner with SeraCare, whose forward thinking and high quality products give IVD developers innovative tools and solutions for their development pipeline. This agreement further validates the use of our ViveST technology and the combined offerings of both companies will be attractive to both point-of-care and centralized diagnostic testing developers,” said Timothy W. Murray, President of ViveBio. “With our ViveST technology, remote specimen collection that is matched with stabilized QC controls will enable diagnostic developers to test more patients with these new diagnostic platforms.”
About SeraCare Life Sciences Inc.
SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).